Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
corolimus
- Development stage
- Unknown
- Lead developer
- Atrium Medical
- Modality
- Small Molecules
- Administration
- Local
01
Overview
Corolimus is a small molecule immunosuppressant, likely a calcineurin inhibitor, developed by Atrium Medical Corporation. It is used as a drug component in the Cinatra™ Corolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries. The drug is designed to prevent neointimal proliferation and restenosis by inhibiting T-cell activation and proliferation, a common mechanism for immunosuppressants in drug-eluting stents.
- Other names
- voclosporin
02
Targets
FKBP1AMechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on corolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on corolimus.